ASND Ascendis Pharma A/S - American Depositary Shares
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Feb 11, 2026
$227.87
· of 52w range
· above low
· to high
$186.0552w low
$282.1552w high
P/E
-56.7
EPS
$-3.76
Revenue
$720M
your badges
52W Range
$186–$282
Analyst Rating
BUY
Price Target
$310
P/E
-56.7
ROE
169.8%
Net Profit Margin
-31.7%
Your badge strip is empty — pin a metric anywhere on this page.
ASND Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$227.87
P/E
-56.7
EPS
$-3.76
Revenue
$720M
ROE
169.8%
52W Range
$186–$282
ASND Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About Ascendis Pharma A/S - American Depositary Shares Company overview from Wikipedia
sectorHealthcare
industryBiotechnology
employees1,189
countryDK
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$720M2017-12-31 → 2025-12-31
EPS$-3.762017-12-31 → 2025-12-31
Free Cash Flow·2017-12-31 → 2023-12-31
Net margin-31.7%2017-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | ASND | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -56.75Y avg ≈-26.1 | ≈-26.1 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | ASND | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin | 86.8%5Y avg ≈83.6% | ≈83.6% | · | · | |
| Operating Margin | -18.9%5Y avg ≈-341.1% | ≈-341.1% | · | · | |
| EBITDA Margin | -18.9%5Y avg ≈-341.1% | ≈-341.1% | · | · | |
| Pretax Margin | -29.5%5Y avg ≈-359.8% | ≈-359.8% | · | · | |
| Net Profit Margin | -31.7%5Y avg ≈-363.9% | ≈-363.9% | · | · | |
| ROA | -18.4%5Y avg ≈-40.0% | ≈-40.0% | · | · | |
| ROE | 169.8%5Y avg ≈-112.4% | ≈-112.4% | · | · | |
| ROIC | 89.8%5Y avg ≈114.8% | ≈114.8% | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | ASND | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio | 1.05Y avg ≈2.8 | ≈2.8 | · | · | |
| Quick Ratio | 0.65Y avg ≈1.4 | ≈1.4 | · | · | |
| Interest Coverage | -1.75Y avg ≈-8.6 | ≈-8.6 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | ASND | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.65Y avg ≈0.3 | ≈0.3 | · | · | |
| Inventory Turnover | 0.35Y avg ≈0.2 | ≈0.2 | · | · | |
| Revenue / Employee | ≈$605.7K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-319.6%
Next Report
Nov 09, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 13, 2026 | $0.72 | $1.41 | -48.9% |
| March 31, 2026 | $-0.77 | $0.21 | -471.1% | |
| Dec. 31, 2025 | $-0.55 | $-0.05 | -1098.3% | |
| Sept. 30, 2025 | $-1.00 | $-0.22 | -345.6% | |
| June 30, 2025 | $-0.64 | $-1.27 | 49.8% | |
| March 31, 2025 | $-1.58 | $-1.52 | -3.7% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $720M | $364M | $267M | $51M | $8M | $7M | $13M | $11M | $2M | $5M | |
| Cost of Revenue | $95M | $44M | $44M | $12M | $4M | $0 | $0 | · | · | · | |
| Gross Profit | $625M | $319M | $222M | $39M | $4M | $7M | $13M | · | · | · | |
| R&D Expense | $304M | $307M | $413M | $380M | $296M | $261M | $192M | $140M | $100M | $66M | |
| SG&A Expense | $458M | $291M | $264M | $221M | $160M | $77M | $48M | $25M | $13M | $12M | |
| Operating Income | $-136M | $-279M | $-456M | $-562M | $-452M | $-331M | $-227M | $-155M | $-112M | $-73M | |
| Interest Expense | $81M | $66M | $44M | $31M | $4M | $2M | $1M | $127.0K | $97.0K | $5.0K | |
| Interest Income | $114M | $26M | $44M | $52M | $60M | $2M | $18M | $25M | $923.0K | $7M | |
| Pretax Income | $-213M | $-373M | $-474M | $-578M | $-384M | $-419M | $-218M | $-130M | $-124M | $-69M | |
| Income Tax | $15M | $5M | $7M | $5M | $-367.0K | $-219.0K | $-234.0K | $-394.0K | $-477.0K | $-227.0K | |
| Net Income | $-228M | $-378M | $-481M | $-583M | $-384M | $-419M | $-218M | $-130M | $-124M | $-69M | |
| EPS (Basic) | $-3.76 | $-6.53 | $-8.55 | $-10.40 | $-7.00 | · | · | · | $-3.68 | $-2.58 | |
| EPS (Diluted) | $-3.76 | $-6.53 | $-8.55 | $-10.40 | $-7.00 | · | · | · | $-3.68 | $-2.58 | |
| Shares (Basic) | 60,607,131 | 57,891,570 | 56,287,060 | 56,071,793 | 54,771,763 | 50,616,528 | 46,506,862 | 41,085,237 | 33,626,305 | 26,564,414 | |
| Shares (Diluted) | · | · | · | · | · | · | · | · | 33,626,305 | 26,564,414 | |
| EBITDA | $-136M | $-279M | $-456M | $-562M | $-452M | $-331M | $-227M | $-155M | $-112M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $616M | $560M | $392M | $445M | $446M | $585M | $598M | $278M | $195M | $180M | |
| Inventory | $302M | $296M | $209M | $131M | $75M | $0 | · | · | · | · | |
| Current Assets | $1.11B | $1.06B | $703M | $923M | $806M | $740M | $611M | $293M | $205M | $184M | |
| PP&E (Net) | $146M | $99M | $111M | $129M | $126M | $108M | $45M | $4M | $3M | $2M | |
| Goodwill | · | · | · | · | · | · | $3M | $3M | $3M | $3M | |
| Total Assets | $1.30B | $1.18B | $826M | $1.09B | $1.08B | $980M | $677M | $319M | $211M | $190M | |
| Accounts Payable | · | · | · | · | · | · | · | · | $24M | $13M | |
| Current Liabilities | $1.07B | $908M | $737M | $171M | $100M | $53M | $48M | $39M | $24M | $13M | |
| Total Liabilities | $1.47B | $1.29B | $971M | $826M | $201M | $141M | $80M | $39M | $24M | $13M | |
| Stockholders' Equity | $-163M | $-106M | $-146M | $263M | $884M | $839M | $597M | $280M | $187M | $177M |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $54M | $-306M | $-467M | $-496M | $-418M | $-272M | $-176M | $-139M | $-95M | $-60M | |
| CapEx | · | · | $2M | $14M | $24M | $20M | $5M | $3M | $941.0K | $672.0K | |
| Investing Cash Flow | $-8M | $7M | $286M | $62M | $-111M | $-291M | $-5M | $-3M | $-941.0K | $-672.0K | |
| Financing Cash Flow | $36M | $444M | $134M | $397M | $351M | $603M | $494M | $203M | $125M | $117M | |
| Free Cash Flow | · | · | $-470M | $-510M | $-441M | $-291M | $-181M | $-141M | $-96M | · | |
| Levered FCF | · | · | $-515M | $-541M | $-445M | $-293M | $-181M | $-142M | $-96M | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.8% | 87.8% | 83.4% | 76.3% | 54.7% | · | · | · | · | · | |
| Operating Margin | -18.9% | -76.7% | -170.8% | -1097.9% | -5808.6% | -4755.1% | -1695.1% | -1462.6% | -7290.3% | · | |
| Net Margin | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% | -6025.5% | -1630.0% | -1229.5% | -8097.8% | · | |
| Pretax Margin | -29.5% | -102.6% | -177.8% | -1129.1% | -4936.3% | -6028.7% | -1631.8% | -1233.3% | -8129.0% | · | |
| EBITDA Margin | -18.9% | -76.7% | -170.8% | -1097.9% | -5808.6% | -4755.1% | -1695.1% | -1462.6% | -7290.3% | · | |
| ROA | -18.4% | -37.7% | -50.3% | -53.6% | -37.2% | -50.6% | -43.8% | -49.1% | -61.8% | · | |
| ROE | 169.8% | 300.8% | -818.4% | -101.7% | -44.5% | -58.4% | -49.7% | -55.7% | -68.1% | · | |
| ROIC | 89.8% | 267.1% | 317.5% | -215.3% | -51.1% | -39.4% | -37.9% | -55.1% | -59.4% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.2 | 3.6 | 5.4 | 8.0 | 14.0 | 12.7 | 7.5 | 8.6 | · | |
| Quick Ratio | 0.6 | 0.6 | 2.0 | 2.6 | 4.4 | 11.1 | 12.5 | 7.1 | 8.2 | · | |
| Interest Coverage | -1.7 | -4.3 | -10.3 | -18.3 | -115.5 | -172.4 | -1095.3 | -1218.6 | -1149.9 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.4 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 0.3 | 0.2 | 0.3 | 0.1 | 0.1 | · | · | · | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | · | · | · | · | · | · | · | · | $0.05 | · | |
| Cash Flow / Share | · | · | · | · | · | · | · | · | $-2.83 | · | |
| EPS (TTM) | $-3.76 | $-6.53 | $-8.55 | $-10.40 | $-7.00 | · | · | · | $-3.68 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $720M | $364M | $267M | $51M | $8M | $7M | $13M | $11M | $2M | · | |
| Net Income TTM | $-228M | $-378M | $-481M | $-583M | $-384M | $-419M | $-218M | $-130M | $-124M | · | |
| P/E | -56.7 | -21.1 | -14.7 | -11.7 | -19.2 | · | · | · | -10.9 | · | |
| Earnings Yield | -1.8% | -4.7% | -6.8% | -8.5% | -5.2% | · | · | · | -9.2% | · |
Per Share
| Metric | Trend | Q4 2016 | Q4 2015 | Q4 2014 |
|---|---|---|---|---|
| EPS (TTM) | $-2.58 | $-1.39 | · |
Valuation (TTM)
| Metric | Trend | Q4 2016 | Q4 2015 | Q4 2014 |
|---|---|---|---|---|
| Revenue TTM | $5M | $8M | · | |
| Net Income TTM | $-69M | $-33M | · | |
| P/E | -7.8 | -13.2 | · | |
| Earnings Yield | -12.8% | -7.6% | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-01-01 | 2022-12-31 |
|---|---|---|---|---|---|
| Revenue | $720M | $364M | $267M | · | $51M |
| Gross Margin % | 86.8% | 87.8% | 83.4% | · | 76.3% |
| Operating Margin % | -18.9% | -76.7% | -170.8% | · | -1097.9% |
| Net Income | $-228M | $-378M | $-481M | · | $-583M |
| Diluted EPS | $-3.76 | $-6.53 | $-8.55 | · | $-10.40 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-01-01 | 2022-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.2 | 3.6 | · | 5.4 |
| Quick Ratio | 0.6 | 0.6 | 2.0 | · | 2.6 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-01-01 | 2022-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | · | · | $-470M | · | $-510M |
Institutional owners (13F) 26 filers · $211.4M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
26
Value held
$211.4M
New positions
2
Exited positions
254
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 2 | 254 | 3 | 1 | · |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair. Change vs prior quarter not shown: filer coverage differs too much between these two quarters for a reliable comparison.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | $60,053,342 | 225,155 | 28.41% | Shares |
| Camber Capital Management LP | $43,150,000 | 250,000 | 20.41% | Shares |
| NEUBERGER BERMAN GROUP LLC | $38,062,278 | 142,705 | 18.01% | Shares |
| ODDO BHF ASSET MANAGEMENT SAS | $34,315,395 | 128,657 | 16.23% | Shares |
| Quadrature Capital Ltd | $10,894,178 | 40,845 | 5.15% | Shares |
| TWO SIGMA ADVISERS, LP | $10,107,576 | 47,400 | 4.78% | Shares |
| Matisse Capital | $5,964,592 | 26,077 | 2.82% | Shares |
| Advisors Asset Management, Inc. | $2,642,897 | 12,394 | 1.25% | Shares |
| CIBC Private Wealth Group LLC | $1,665,630 | 8,378 | 0.79% | Shares |
| Skopos Labs, Inc. | $931,389 | 4,072 | 0.44% | Shares |
| Asset Management One Co., Ltd. | $870,318 | 3,805 | 0.41% | Shares |
| FERGUSON WELLMAN CAPITAL MANAGEMENT, INC | $693,472 | 2,600 | 0.33% | Shares |
| MidWestOne Financial Group, Inc. | $654,007 | 3,067 | 0.31% | Shares |
| DEARBORN PARTNERS LLC | $346,736 | 1,300 | 0.16% | Shares |
| Springhill Fund Asset Management (HK) Co Ltd | $338,684 | 2,173 | 0.16% | Shares |
| CWM, LLC | $308,099 | 1,347 | 0.15% | Shares |
| Shilanski & Associates, Inc. | $259,248 | 1,304 | 0.12% | Shares |
| Lindbrook Capital, LLC | $44,264 | 284 | 0.02% | Shares |
| FTB Advisors, Inc. | $40,561 | 235 | 0.02% | Shares |
| E Fund Management (Hong Kong) Co., Ltd. | $22,404 | 84 | 0.01% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $10,293 | 45 | 0.00% | Shares |
| Ninepoint Partners LP | $6,935 | 26 | 0.00% | Shares |
| Handelsbanken Fonder AB | $3,538 | 15,467 | 0.00% | Shares |
| IFP Advisors, Inc | $3,423 | 14 | 0.00% | Shares |
| Binnacle Investments Inc | $596 | 3 | 0.00% | Shares |
| HUNTINGTON NATIONAL BANK | $244 | 1 | 0.00% | Shares |
Activists & 5%+ owners 5 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC, OrbiMed Capital GP V LLC, OrbiMed Global Healthcare GP LLC, OrbiMed Capital LLC ×16 filings | May 22, 2020 | · | Initial filing | · | SEC |
| Vivo Ventures VII, LLC, Vivo Ventures Fund VII, L.P., Vivo Ventures VII Affiliates Fund, L.P., Vivo Opportunity, LLC, Vivo Opportunity Fund, L.P. ×3 filings | Oct. 23, 2019 | · | Initial filing | · | SEC |
| Sofinnova Venture Partners IX, L.P. (“SVP IX”), Sofinnova Management IX, L.L.C. (“SM IX”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Dr. Anand Mehra (“Mehra”) ×5 filings | Feb. 12, 2019 | · | Initial filing | Passive investment | SEC |
| Sofinnova Capital V FCPR (“SC V”), Sofinnova Partners SAS, a French corporation (“SP SAS”), Denis Lucquin (“Lucquin”), Antoine Papiernik (“Papiernik”), Monique Saulnier (“Saulnier”) ×3 filings | Feb. 14, 2018 | · | Initial filing | · | SEC |
| Vivo Ventures VII, LLC FEIN, Vivo Ventures Fund VII, L.P. FEIN, Vivo Ventures VII Affiliates Fund, L.P. FEIN | Feb. 17, 2015 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 5 insiders · 3 officers · 2 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Scott Thomas Smith | EVP & Chief Financial Officer | June 2, 2026 P | 4,367 | 2 | 0 | $77,730 |
| Mads Bodenhoff | SVP & PAO | Sept. 8, 2026 M | 0 | 0 | 1 | $-810,570 |
| Flemming Steen Jensen | EVP & Product Supply and Quality | May 11, 2026 S | 0 | 0 | 1 | $-4,641,015 |
| Lars Holtug | Director | Sept. 2, 2026 S | 4,000 | 0 | 1 | $-62,335 |
| Jean Jacques Bienaime | Director | April 14, 2026 A | 2,900 | 7 | 0 | $699,338 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 20 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IBB · iShares Trust | 1.20% | 472,545 SH | Sept. 11, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.92% | 4,352 SH | Oct. 1, 2026 | Daily |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 0.71% | 36,364 SH | Oct. 1, 2026 | Daily |
| IWP · iShares Trust | 0.36% | 264,896 SH | Sept. 11, 2026 | Daily |
| IDHQ · Invesco Exchange-Traded Fund Trust … | 0.24% | 11,454 SH | Oct. 1, 2026 | Daily |
| IYH · iShares Trust | 0.21% | 29,076 SH | Sept. 11, 2026 | Daily |
| SMMD · iShares Trust | 0.18% | 26,541 SH | Sept. 11, 2026 | Daily |
| IWR · iShares Trust | 0.10% | 204,724 SH | Sept. 11, 2026 | Daily |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.08% | 2,889 SH | Oct. 1, 2026 | Daily |
| PDN · Invesco Exchange-Traded Fund Trust … | 0.06% | 872 SH | Oct. 1, 2026 | Daily |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 74,541 SH | Aug. 19, 2026 | Daily |
| IWF · iShares Trust | 0.04% | 176,655 SH | Sept. 11, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.02% | 8,179 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 4,200 SH | Aug. 19, 2026 | Daily |
| IWB · iShares Trust | 0.02% | 34,351 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.02% | 13,687 SH | Sept. 11, 2026 | Daily |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.01% | 2,134 SH | Oct. 1, 2026 | Daily |
| IWS · iShares Trust | 0.01% | 4,100 SH | Sept. 10, 2026 | Daily |
| IWD · iShares Trust | 0.00% | 6,108 SH | Sept. 11, 2026 | Daily |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.00% | 1,675 SH | Aug. 19, 2026 | Daily |
ASND Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 28 analysts
BUY
Median target
$316.57
+38.9%
12 42.9%
Strong Buy
15 53.6%
Buy
1 3.6%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
20 analysts · 2026-09-30Mean target $309.81 +36.0%
← Below all targets
Current price $227.87
Low$265.74
Mean$309.81
High$354.56
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ASND | · | -56.7 | · | -31.7% | 169.8% | 86.8% |
| EVAX | · | · | · | -102.4% | -16.2% | · |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 20-F filed Feb 11, 2026